This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.


A leading US pharmaceutical company, AbbVie, has taken legal action against Europe’s medicines regulator to try to prevent it from releasing data it holds on the safety and efficacy of one of its drugs.

If successful, the action could jeopardise the European agency’s plans to begin publishing from January 2014 all clinical trial data once it has decided whether to approve a drug for use across the European Union.1

AbbVie has sought an injunction to stop the European Medicines Agency (EMA) from releasing detailed information that it holds on its drug Humira (adalimumab) for rheumatoid arthritis. The move follows two freedom of information requests from Belgian pharmaceutical company UCB in late 2012 for patient level data on the drug’s side effects …

Link to access full article:


Data Sharing  


Archive  data sharing